Rong Fu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rong Fu has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Hong-Yang Zhao
Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
2 shared publicationsLin Li
Department of Neurosurgery, Union Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan Hubei China
2 shared publications- Chen Qian
Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
1 shared publication Hai-Jun Wang
Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
1 shared publicationJin Rao
Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
1 shared publication- Jin Yao
Department of Radiology, West China Hospital of Sichuan University, Chengdu, China
1 shared publication
Latest Publications
- Open Access
- 6 February 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (2) , e010782
UBE2T/CDC42/CD276 signaling axis mediates brain metastasis of triple-negative breast cancer via lysosomal autophagy
Background: Advanced triple-negative breast cancer (TNBC) is prone to brain metastasis (BrM). The precise molecular mechanism responsible for this phenomenon has not yet been completely established, so it is vital to comprehend the molecular mechanism behind it. Methods: The protein chip analysis was conducted to identify any abnormal UBE2T protein expression in TNBC, especially BrM. Here, we used public databases and bioinformatics analysis as well as clinical samples from different cohorts to investigate the interrelationship between UBE2T/CDC42/CD276. This predicted relationship was then repeatedly validated using different in vivo and in vitro experimental methods. Additionally, multiple experimental approaches were implemented, encompassing western blotting, Co-IP, GST pull-down, flow cytometry, mass spectrometry, immunofluorescence, immunohistochemistry, and qRT-PCR to reveal the molecular mechanism of UBE2T-mediated immune escape and BrM. Results: Our results indicate that expressed at elevated levels in breast cancer, UBE2T is negatively linked to patient prognosis, especially in BrM of TNBC. Data from clinical samples from our different cohorts and TCGA indicate a significant correlation between UBE2T and immunosuppression. Mechanistically, UBE2T directly interacts with CDC42, promoting its K48-linked polyubiquitination and proteasomal degradation, thereby inhibiting CDC42 from degrading CD276 via the autophagy-lysosomal pathway, indirectly upregulating CD276 and thereby impairing the CD8+ T cells function, ultimately mediating tumor immune escape and BrM. Finally, animal experimental results also showed that inhibition of UBE2T elevated the TNBC sensitivity to immune checkpoint CD276 blockade and inhibited BrM of TNBC. Conclusions: In conclusion, our results indicate a new mechanism whereby UBE2T-mediated ubiquitination positively controls the UBE2T/CDC42/CD276 axis to upregulate tumor cell expression of CD276 and thereby impair CD8+ T cells function, ultimately leading to tumor cell immune escape and BrM.
- 6 February 2025
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 13 (2) , e010782
Open AccessUBE2T/CDC42/CD276 signaling axis mediates brain metastasis of triple-negative breast cancer via lysosomal autophagy
Background: Advanced triple-negative breast cancer (TNBC) is prone to brain metastasis (BrM). The precise molecular mechanism responsible for this phenomenon has not yet been completely established, so it is vital to comprehend the molecular mechanism behind it. Methods: The protein chip analysis was conducted to identify any abnormal UBE2T protein expression in TNBC, especially BrM. Here, we used public databases and bioinformatics analysis as well as clinical samples from different cohorts to investigate the interrelationship between UBE2T/CDC42/CD276. This predicted relationship was then repeatedly validated using different in vivo and in vitro experimental methods. Additionally, multiple experimental approaches were implemented, encompassing western blotting, Co-IP, GST pull-down, flow cytometry, mass spectrometry, immunofluorescence, immunohistochemistry, and qRT-PCR to reveal the molecular mechanism of UBE2T-mediated immune escape and BrM. Results: Our results indicate that expressed at elevated levels in breast cancer, UBE2T is negatively linked to patient prognosis, especially in BrM of TNBC. Data from clinical samples from our different cohorts and TCGA indicate a significant correlation between UBE2T and immunosuppression. Mechanistically, UBE2T directly interacts with CDC42, promoting its K48-linked polyubiquitination and proteasomal degradation, thereby inhibiting CDC42 from degrading CD276 via the autophagy-lysosomal pathway, indirectly upregulating CD276 and thereby impairing the CD8+ T cells function, ultimately mediating tumor immune escape and BrM. Finally, animal experimental results also showed that inhibition of UBE2T elevated the TNBC sensitivity to immune checkpoint CD276 blockade and inhibited BrM of TNBC. Conclusions: In conclusion, our results indicate a new mechanism whereby UBE2T-mediated ubiquitination positively controls the UBE2T/CDC42/CD276 axis to upregulate tumor cell expression of CD276 and thereby impair CD8+ T cells function, ultimately leading to tumor cell immune escape and BrM.
- Open Access
- 1 September 2024
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 30 (9) , e70017
RNF122 promotes glioblastoma growth via the JAK2/STAT3/c‐Myc signaling Axis
Objective: The E3 ubiquitin ligase is well recognized as a significant contributor to glioblastoma (GBM) progression and has promise as a prospective therapeutic target. This study explores the contribution of E3 ubiquitin ligase RNF122 in the GBM progression and the related molecular mechanisms.Methods: RNF122 expression levels were evaluated using qRT‐PCR, WB, and IHC, while functional assays besides animal experiments were used to assess RNF122's effect on GBM progression. We also tested the RNF122 impact on JAK2/STAT3/c‐Myc signaling using WB.Results: RNF122 was upregulated in GBM and correlated to the advanced stage and poor clinical outcomes, representing an independent prognostic factor. Based on functional assays, RNF122 promotes GBM growth and cell cycle, which was validated further in subsequent analyses by JAK2/STAT3/c‐Myc pathway activation. Moreover, JAK2/STAT3 signaling pathway inhibitor WP1066 can weaken the effect of overexpression RNF122 on promoting GBM progression.Conclusion: Our results revealed that RNF122 caused an aggressive phenotype to GBM and was a poor prognosticator; thus, targeting RNF122 may be effectual in GBM treatment.
- 1 September 2024
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 30 (9) , e70017
Open AccessRNF122 promotes glioblastoma growth via the JAK2/STAT3/c‐Myc signaling Axis
Objective: The E3 ubiquitin ligase is well recognized as a significant contributor to glioblastoma (GBM) progression and has promise as a prospective therapeutic target. This study explores the contribution of E3 ubiquitin ligase RNF122 in the GBM progression and the related molecular mechanisms.Methods: RNF122 expression levels were evaluated using qRT‐PCR, WB, and IHC, while functional assays besides animal experiments were used to assess RNF122's effect on GBM progression. We also tested the RNF122 impact on JAK2/STAT3/c‐Myc signaling using WB.Results: RNF122 was upregulated in GBM and correlated to the advanced stage and poor clinical outcomes, representing an independent prognostic factor. Based on functional assays, RNF122 promotes GBM growth and cell cycle, which was validated further in subsequent analyses by JAK2/STAT3/c‐Myc pathway activation. Moreover, JAK2/STAT3 signaling pathway inhibitor WP1066 can weaken the effect of overexpression RNF122 on promoting GBM progression.Conclusion: Our results revealed that RNF122 caused an aggressive phenotype to GBM and was a poor prognosticator; thus, targeting RNF122 may be effectual in GBM treatment.
- Open Access
- 11 April 2024
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (4) , e008718
OMA1 competitively binds to HSPA9 to promote mitophagy and activate the cGAS–STING pathway to mediate GBM immune escape
Background Immunotherapy with checkpoint inhibitors, especially those targeting programmed death receptor 1 (PD-1)/PD-1 ligand (PD-L1), is increasingly recognized as a highly promising therapeutic modality for malignancies. Nevertheless, the efficiency of immune checkpoint blockade therapy in treating glioblastoma (GBM) is constrained. Hence, it is imperative to expand our comprehension of the molecular mechanisms behind GBM immune escape (IE). Methods Protein chip analysis was performed to screen aberrantly expressed OMA1 protein in PD-1 inhibitor sensitive or resistant GBM. Herein, public databases and bioinformatics analysis were employed to investigate the OMA1 and PD-L1 relation. Then, this predicted relation was verified in primary GBM cell lines through distinct experimental methods. To investigate the molecular mechanism behind OMA1 in immunosuppression, a series of experimental methods were employed, including Western blotting, co-immunoprecipitation (Co-IP), mass spectrometry (MS), immunofluorescence, immunohistochemistry, and qRT-PCR. Results Our findings revealed that OMA1 competitively binds to HSPA9 to induce mitophagy and mediates the IE of GBM. Data from TCGA indicated a significant correlation between OMA1 and immunosuppression. OMA1 promoted PD-L1 levels in primary cells from patients with GBM. Next, the results of Co-IP and MS conducted on GBM primary cells revealed that OMA1 interacts with HSPA9 and induces mitophagy. OMA1 promoted not only cGAS–STING activity by increasing mitochondrial DNA release but also PD-L1 transcription by activating cGAS–STING. Eventually, OMA1 has been found to induce immune evasion in GBM through its regulation of PD-1 binding and PD-L1 mediated T cell cytotoxicity. Conclusions The OMA1/HSPA9/cGAS/PD-L1 axis is elucidated in our study as a newly identified immune therapeutic target in GBM.
- 11 April 2024
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (4) , e008718
Open AccessOMA1 competitively binds to HSPA9 to promote mitophagy and activate the cGAS–STING pathway to mediate GBM immune escape
Background Immunotherapy with checkpoint inhibitors, especially those targeting programmed death receptor 1 (PD-1)/PD-1 ligand (PD-L1), is increasingly recognized as a highly promising therapeutic modality for malignancies. Nevertheless, the efficiency of immune checkpoint blockade therapy in treating glioblastoma (GBM) is constrained. Hence, it is imperative to expand our comprehension of the molecular mechanisms behind GBM immune escape (IE). Methods Protein chip analysis was performed to screen aberrantly expressed OMA1 protein in PD-1 inhibitor sensitive or resistant GBM. Herein, public databases and bioinformatics analysis were employed to investigate the OMA1 and PD-L1 relation. Then, this predicted relation was verified in primary GBM cell lines through distinct experimental methods. To investigate the molecular mechanism behind OMA1 in immunosuppression, a series of experimental methods were employed, including Western blotting, co-immunoprecipitation (Co-IP), mass spectrometry (MS), immunofluorescence, immunohistochemistry, and qRT-PCR. Results Our findings revealed that OMA1 competitively binds to HSPA9 to induce mitophagy and mediates the IE of GBM. Data from TCGA indicated a significant correlation between OMA1 and immunosuppression. OMA1 promoted PD-L1 levels in primary cells from patients with GBM. Next, the results of Co-IP and MS conducted on GBM primary cells revealed that OMA1 interacts with HSPA9 and induces mitophagy. OMA1 promoted not only cGAS–STING activity by increasing mitochondrial DNA release but also PD-L1 transcription by activating cGAS–STING. Eventually, OMA1 has been found to induce immune evasion in GBM through its regulation of PD-1 binding and PD-L1 mediated T cell cytotoxicity. Conclusions The OMA1/HSPA9/cGAS/PD-L1 axis is elucidated in our study as a newly identified immune therapeutic target in GBM.
- Open Access
- 10 August 2021
- Published by Springer Nature in Research Square
Inhibition of Arginyl-tRNA Synthetase Promotes the Protection of Neuronal Ischemic Tolerance in Vitro Author Imformation
BackgroundsStudies have shown that the metabolic rate of mammals decreases during hibernation, suggesting that effective reduction of the energy consumption of ischemic cells may be the basis of the protective effect of ischemic tolerance. Anderson et al. reported after inhibition of the gene encoding arginyl-tRNA synthetase, the protein translation and mortality in C. elegans under anoxic conditions decreased significantly.PurposesWhether inhibition of arginyl-tRNA synthetase (RARS), in addition to combating hypoxic injury in C. elegans, protects rat neurons from ischemic damage remains unknown. The aim of this study is to determine whether knockdown of arginyl-tRNA synthetase improves the tolerance of primary cultured rat neurons to ischemic anoxia. Methods For the primary neuronal cutlure, cerebral cortex tissues were collected from newborn 24 hours Sprague-Dawley rats. Different viral vectors were transfected into cultured primary neurons, and the optimal viral vector and time points for gene silencing were determined by detecting the expression of RARS gene and protein. The adenovirus vector expressing shRNA-RARS with the highest silencing efficiency was transfected into rat primary cultured cortical neurons. The time point at which the viral vector exhibits optimal gene silencing efficiency was selected as the detection time point for subsequent experiments. The neurons after OGD treatment were divided into 2 groups: the experimental group and the control group. Each group was divided into 3 subgroups: the normal group, the control shRNA group and the shRNA-RARS group. After 3 hours of OGD treatment, cell survival, ATP levels and RARS protein expression were evaluated , and the data was analyzed. ResultsPrimary cultured neurons were identified and purified. The adenoviral vector expressing RARS-RNAi (27394-1) exhibited the highest silencing efficiency of the three adenoviral vectors, and 3 days after transfection of the adenoviral vector was selected as the optimal time point for gene silencing. Transfection of adenoviral vectors expressing shRNA-RARS reduced RARS protein expression, ATP consumption and neuronal death, and increased CCK8 activity in neurons after OGD insult.Conclusions Our work revealed neurons transfected with adenoviral vectors expressing shRNA-RARS exhibited stronger tolerance to ischemia and hypoxia, which was due to the inhibition of RARS activity andreduced cell energy metabolism rate. These results suggested that RARS inhibition reduced protein translation and energy consumption, and played a protective role in ischemic tolerance.
- 10 August 2021
- Published by Springer Nature in Research Square
Open AccessInhibition of Arginyl-tRNA Synthetase Promotes the Protection of Neuronal Ischemic Tolerance in Vitro Author Imformation
BackgroundsStudies have shown that the metabolic rate of mammals decreases during hibernation, suggesting that effective reduction of the energy consumption of ischemic cells may be the basis of the protective effect of ischemic tolerance. Anderson et al. reported after inhibition of the gene encoding arginyl-tRNA synthetase, the protein translation and mortality in C. elegans under anoxic conditions decreased significantly.PurposesWhether inhibition of arginyl-tRNA synthetase (RARS), in addition to combating hypoxic injury in C. elegans, protects rat neurons from ischemic damage remains unknown. The aim of this study is to determine whether knockdown of arginyl-tRNA synthetase improves the tolerance of primary cultured rat neurons to ischemic anoxia. Methods For the primary neuronal cutlure, cerebral cortex tissues were collected from newborn 24 hours Sprague-Dawley rats. Different viral vectors were transfected into cultured primary neurons, and the optimal viral vector and time points for gene silencing were determined by detecting the expression of RARS gene and protein. The adenovirus vector expressing shRNA-RARS with the highest silencing efficiency was transfected into rat primary cultured cortical neurons. The time point at which the viral vector exhibits optimal gene silencing efficiency was selected as the detection time point for subsequent experiments. The neurons after OGD treatment were divided into 2 groups: the experimental group and the control group. Each group was divided into 3 subgroups: the normal group, the control shRNA group and the shRNA-RARS group. After 3 hours of OGD treatment, cell survival, ATP levels and RARS protein expression were evaluated , and the data was analyzed. ResultsPrimary cultured neurons were identified and purified. The adenoviral vector expressing RARS-RNAi (27394-1) exhibited the highest silencing efficiency of the three adenoviral vectors, and 3 days after transfection of the adenoviral vector was selected as the optimal time point for gene silencing. Transfection of adenoviral vectors expressing shRNA-RARS reduced RARS protein expression, ATP consumption and neuronal death, and increased CCK8 activity in neurons after OGD insult.Conclusions Our work revealed neurons transfected with adenoviral vectors expressing shRNA-RARS exhibited stronger tolerance to ischemia and hypoxia, which was due to the inhibition of RARS activity andreduced cell energy metabolism rate. These results suggested that RARS inhibition reduced protein translation and energy consumption, and played a protective role in ischemic tolerance.
- 28 July 2016
- Published by Springer Nature in Current Medical Science
- Vol. 36 (4) , 554-557
Ischemic preconditioning inhibits over-expression of arginyl-tRNA synthetase gene Rars in ischemia-injured neurons
- 28 July 2016
- Published by Springer Nature in Current Medical Science
- Vol. 36 (4) , 554-557
Ischemic preconditioning inhibits over-expression of arginyl-tRNA synthetase gene Rars in ischemia-injured neurons
- 8 April 2014
- Published by Springer Nature in Current Medical Science
- Vol. 34 (2) , 172-175
Expression of arginyl-tRNA synthetase in rats with focal cerebral ischemia
- 8 April 2014
- Published by Springer Nature in Current Medical Science
- Vol. 34 (2) , 172-175
Expression of arginyl-tRNA synthetase in rats with focal cerebral ischemia